169 related articles for article (PubMed ID: 19901960)
41. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
42. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1.
Ohtsu K; Hiyama E; Ichikawa T; Matsuura Y; Yokoyama T
Clin Cancer Res; 1997 Jul; 3(7):1221-8. PubMed ID: 9815803
[TBL] [Abstract][Full Text] [Related]
43. Distinct cytogenetic pathways of advanced-stage neuroblastoma tumors, detected by spectral karyotyping.
Stark B; Jeison M; Bar-Am I; Glaser-Gabay L; Mardoukh J; Luria D; Feinmesser M; Goshen Y; Stein J; Abramov A; Zaizov R; Yaniv I
Genes Chromosomes Cancer; 2002 Jul; 34(3):313-24. PubMed ID: 12007192
[TBL] [Abstract][Full Text] [Related]
44. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
[TBL] [Abstract][Full Text] [Related]
45. Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death.
Ejeskär K; Krona C; Carén H; Zaibak F; Li L; Martinsson T; Ioannou PA
BMC Cancer; 2005 Dec; 5():161. PubMed ID: 16359544
[TBL] [Abstract][Full Text] [Related]
46. High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome.
Schramm A; von Schuetz V; Christiansen H; Havers W; Papoutsi M; Wilting J; Schweigerer L
Oncogene; 2005 Jan; 24(4):680-7. PubMed ID: 15580313
[TBL] [Abstract][Full Text] [Related]
47. 11q deletion in neuroblastoma: a review of biological and clinical implications.
Mlakar V; Jurkovic Mlakar S; Lopez G; Maris JM; Ansari M; Gumy-Pause F
Mol Cancer; 2017 Jun; 16(1):114. PubMed ID: 28662712
[TBL] [Abstract][Full Text] [Related]
48. Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma.
Yang L; Li Y; Wei Z; Chang X
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2341-2348. PubMed ID: 29247836
[TBL] [Abstract][Full Text] [Related]
49. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.
Ackermann S; Kocak H; Hero B; Ehemann V; Kahlert Y; Oberthuer A; Roels F; Theißen J; Odenthal M; Berthold F; Fischer M
BMC Cancer; 2014 Nov; 14():840. PubMed ID: 25406647
[TBL] [Abstract][Full Text] [Related]
50. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?
Stallings RL; Howard J; Dunlop A; Mullarkey M; McDermott M; Breatnach F; O'Meara A
Cancer Genet Cytogenet; 2003 Jan; 140(2):133-7. PubMed ID: 12645651
[TBL] [Abstract][Full Text] [Related]
51. Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.
Villamón E; Berbegall AP; Piqueras M; Tadeo I; Castel V; Djos A; Martinsson T; Navarro S; Noguera R
PLoS One; 2013; 8(1):e53740. PubMed ID: 23341988
[TBL] [Abstract][Full Text] [Related]
52. Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.
Sanmartín E; Muñoz L; Piqueras M; Sirerol JA; Berlanga P; Cañete A; Castel V; Font de Mora J
Clin Cancer Res; 2017 Nov; 23(22):6875-6887. PubMed ID: 28830922
[No Abstract] [Full Text] [Related]
53. Bioinformatics analysis of miRNAs in the neuroblastoma 11q-deleted region reveals a role of miR-548l in both 11q-deleted and MYCN amplified tumour cells.
Jurcevic S; Keane S; Borgmästars E; Lubovac-Pilav Z; Ejeskär K
Sci Rep; 2022 Nov; 12(1):19729. PubMed ID: 36396668
[TBL] [Abstract][Full Text] [Related]
54. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
[TBL] [Abstract][Full Text] [Related]
55. New genetic loci in neuroblastoma.
Schwab M; Corvi R; Savelyeva L
Klin Padiatr; 1997; 209(4):147-9. PubMed ID: 9293445
[TBL] [Abstract][Full Text] [Related]
56. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.
Guo C; White PS; Hogarty MD; Brodeur GM; Gerbing R; Stram DO; Maris JM
Med Pediatr Oncol; 2000 Dec; 35(6):544-6. PubMed ID: 11107113
[TBL] [Abstract][Full Text] [Related]
57. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma.
Santo EE; Ebus ME; Koster J; Schulte JH; Lakeman A; van Sluis P; Vermeulen J; Gisselsson D; Øra I; Lindner S; Buckley PG; Stallings RL; Vandesompele J; Eggert A; Caron HN; Versteeg R; Molenaar JJ
Oncogene; 2012 Mar; 31(12):1571-81. PubMed ID: 21860421
[TBL] [Abstract][Full Text] [Related]
58. Risk estimation of neuroblastoma patients using molecular markers.
Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
[TBL] [Abstract][Full Text] [Related]
59. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
[TBL] [Abstract][Full Text] [Related]
60. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization.
Breen CJ; O'Meara A; McDermott M; Mullarkey M; Stallings RL
Cancer Genet Cytogenet; 2000 Jul; 120(1):44-9. PubMed ID: 10913676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
